Emerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing (Record no. 4629)

MARC details
000 -LEADER
fixed length control field 01384 a2200337 4500
001 - CONTROL NUMBER
control field 1498704166
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250317111607.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 250312042016xx 30 eng
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781498704168
037 ## - SOURCE OF ACQUISITION
Source of stock number/acquisition Taylor & Francis
Terms of availability GBP 48.99
Form of issue BB
040 ## - CATALOGING SOURCE
Original cataloging agency 01
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title eng
072 7# - SUBJECT CATEGORY CODE
Subject category code TDCW
Source thema
072 7# - SUBJECT CATEGORY CODE
Subject category code MBNS
Source thema
072 7# - SUBJECT CATEGORY CODE
Subject category code PS
Source thema
072 7# - SUBJECT CATEGORY CODE
Subject category code PBT
Source thema
072 7# - SUBJECT CATEGORY CODE
Subject category code TDCW
Source bic
072 7# - SUBJECT CATEGORY CODE
Subject category code MBNS
Source bic
072 7# - SUBJECT CATEGORY CODE
Subject category code PS
Source bic
072 7# - SUBJECT CATEGORY CODE
Subject category code PBT
Source bic
072 7# - SUBJECT CATEGORY CODE
Subject category code MAT029000
Source bisac
072 7# - SUBJECT CATEGORY CODE
Subject category code MED071000
Source bisac
072 7# - SUBJECT CATEGORY CODE
Subject category code MED090000
Source bisac
072 7# - SUBJECT CATEGORY CODE
Subject category code 615.19
Source bisac
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Harry Yang
245 10 - TITLE STATEMENT
Title Emerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing
250 ## - EDITION STATEMENT
Edition statement 1
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Chapman and Hall/CRC
Date of publication, distribution, etc. 20161130
300 ## - PHYSICAL DESCRIPTION
Extent 386 p
520 ## - SUMMARY, ETC.
Expansion of summary note The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-depth explanations of advanced statistical methods with real-life case studies that illustrate practical applications of these methods in QbD implementation.

No items available.